148291-65-0 Usage
Uses
Used in Pharmaceutical Industry:
(E)-7-Carboxy-3-((6-(4-methoxyphenyl)-5-hexenyl)oxy)-9-oxo-9H-xanthene-4-propanoic acid is used as a potential drug candidate for its anti-inflammatory, antioxidant, and antimicrobial properties. The xanthene core and the functional groups present in the molecule allow it to interact with biological targets, making it a promising compound for the development of new medications.
Used in Drug Design and Development:
(E)-7-Carboxy-3-((6-(4-methoxyphenyl)-5-hexenyl)oxy)-9-oxo-9H-xanthene -4-propanoic acid is used as a structural framework for designing new drugs, particularly in the pharmaceutical industry. The presence of the methoxy group may enhance the bioavailability and pharmacokinetics of the compound, which are crucial factors in drug development. Researchers can utilize (E)-7-Carboxy-3-((6-(4-methoxyphenyl)-5-hexenyl)oxy)-9-oxo-9H-xanthene -4-propanoic acid as a starting point to synthesize new molecules with improved properties and targeted applications.
Used in Chemical Research:
(E)-7-Carboxy-3-((6-(4-methoxyphenyl)-5-hexenyl)oxy)-9-oxo-9H-xanthene-4-propanoic acid serves as a subject of study in chemical research, where its properties, reactivity, and potential interactions with biological systems can be explored. Understanding the compound's behavior can lead to the discovery of new applications and insights into its potential uses in various industries.
Additional research is necessary to fully comprehend the potential uses and effects of (E)-7-Carboxy-3-((6-(4-methoxyphenyl)-5-hexenyl)oxy)-9-oxo-9H-xanthene-4-propanoic acid, as its complex structure and functional groups offer a wide range of possibilities in different fields.
Check Digit Verification of cas no
The CAS Registry Mumber 148291-65-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,8,2,9 and 1 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 148291-65:
(8*1)+(7*4)+(6*8)+(5*2)+(4*9)+(3*1)+(2*6)+(1*5)=150
150 % 10 = 0
So 148291-65-0 is a valid CAS Registry Number.
InChI:InChI=1/C30H28O8/c1-36-21-10-7-19(8-11-21)6-4-2-3-5-17-37-25-15-12-23-28(33)24-18-20(30(34)35)9-14-26(24)38-29(23)22(25)13-16-27(31)32/h4,6-12,14-15,18H,2-3,5,13,16-17H2,1H3,(H,31,32)(H,34,35)/b6-4+
148291-65-0Relevant academic research and scientific papers
Design, Synthesis, and Pharmacological Evaluation of Potent Xanthone Dicarboxylic Acid Leukotriene B4 Receptor Antagonists
Jackson, William T.,Boyd, Robert J.,Froelich, Larry L.,Gapinski, D. Mark,Mallett, Barbara E.,Sawyer, J. Scott
, p. 1726 - 1734 (2007/10/02)
In an effort to develop increasingly potent and specific leukotriene B4(LTB4) receptor antagonists, several xanthone dicarboxylic acids were synthesized and evaluated.Two separate synthetic routes were used to construct a xanthone nucleus containing a regiospecific orientation of each carboxylic acid pharmacophore.These compounds represent the major conformationally-restricted analogues of benzophenone dicarboxylic acids previously shown to antagonize the activation of human neutrophils by LTB4.The most potent agent was compound 32, which inhibited the specific binding of LTB4 to receptors on intact human neutrophils (IC50, 6.2 +/- 0.1 nM), LTB4-induced luminol-dependent chemiluminescence (IC50, 55 +/- 11 nM), aggregation (IC50, 133 +/- 42 nM), and chemotaxis (IC50, 899 +/- 176 nM).The compound was a poor antagonist of N-formyl-L-methionyl-L-leucyl-L-phenylalanine-induced chemiluminescence (IC50, 1599 +/- 317 nM) and aggregation (IC50, 2166 +/- 432 nM), indicating specificity in the inhibition of LTB4-stimulated events.Compound 32(LY210073), which was completely devoid of agonist activity, appears to be one of the strongest inhibitors of LTB4 receptor binding reported so far.
Leukotriene antagonists
-
, (2008/06/13)
This invention provides tricyclic derivatives which are leukotriene B4 antagonists, formulations of those derivatives, and a method of using those derivatives for the treatment of conditions characterized by an excessive release of leukotrienes
